CTLA4 and melanoma: In a phase II trial including 26 patients with advanced melanoma treated by ILI with melphalan and the CTLA-4 inhibitor ipilimumab, the ORR was 85%, including 62% CR [49]There is also preclinical evidence that PD-1 inhibition could potentially increase the efficacy of ILP, and these findings further support the rationale behind ongoing studies, evaluating the combination of regional therapy and immunotherapy [50].